Title

Post-vaccination chemosensory outcomes in COVID-19-associated dysfunction

Running title:
COVID-19 vaccination and chemosensory outcomes

Authors
Sachiko Koyama[1], Carla Mucignat-Caretta[2], Maria A. Klyuchnikova[3], Tatiana K. Laktionova[3], Svetlana Kopishinskaia[4], Ilya G. Kvasha[3], Junpeng Ye[5], Elena Cantone[6], Shima Parsa[7], Maria Dolors Guàrdia[8], Valentin Hivert[5], Solal Chauquet[5], Jingguo Chen[9], Giulio Centorame[5], Valentina Parma[10], Kathrin Ohla[11], Vera V. Voznessenskaya[3], Liang-Dar Hwang[5]

Affiliation
[1]Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
[2]Department of Molecular Medicine, University of Padova, Padova, Italy
[3]Severtsov Institute of Ecology & Evolution, Russian Academy of Sciences, Moscow, Russia
[4]Centre de Recherche du CHU de Québec, Laval University, Quebec, Canada
[5]Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
[6]Department of Neuroscience, Reproductive and Dentistry Science, ENT Unit, Federico II University of Naples, Naples, Italy
[7]Shiraz Institute for Stem Cell & Regenerative Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
[8]Food Quality and Technology, IRTA-Food Research Institute, Monells, Spain
[9]The Department of Otolaryngology Head and Neck Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
[10]Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA
[11]Science & Research, dsm-firmenich, Satigny, Switzerland

Correspondence to be sent to:
Liang-Dar Hwang, Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Road, St Lucia, QLD 4072, Australia.
Email: d.hwang@uq.edu.au

ABSTRACT

Olfactory and taste dysfunction are common symptoms of COVID-19 and post-acute COVID-19 syndrome, yet the effects of COVID-19 vaccines on chemosensory perception remain incompletely understood. This global, multilingual, online survey assessed post-vaccination changes in chemosensory function among individuals with and without COVID-19-related chemosensory impairment. Between May 2022 and August 2023, 2,955 responses were collected via convenience sampling, of which 1,352 were included in the analyses. Participants reported vaccination status, side effects, and chemosensory function before and after each vaccine dose. Pfizer-BioNTech accounted for 46.2% of doses, followed by Sputnik V (16.3%), Moderna (15.4%), AstraZeneca (8.9%), and Sinopharm (7.4%). More than 90% of participants reported no change in their general sense of smell or taste following vaccination, regardless of pre-existing chemosensory impairment. Among participants with qualitative chemosensory distortions (one-third of the sample), improvement was reported by 11-18% for parosmia, 20-29% for phantosmia, and 12-21% for taste distortion, depending on the vaccine dose, while worsening was reported by 3% or fewer. Side effects varied by vaccine type and were more frequent among individuals with worsened chemosensory symptoms. These findings suggest that COVID-19 vaccination is unlikely to adversely affect chemosensory function for most individuals. Given the observational design and reliance on self-reported data, the results should be interpreted cautiously. Future longitudinal studies using objective measures are needed to clarify these associations.

Keywords: COVID-19, vaccines, olfactory disorders, parosmia, phantosmia, post-acute COVID-19 syndrome

INTRODUCTION

Following the emergence of COVID-19 (Coronavirus disease 2019), caused by SARS-CoV-2, unprecedented global efforts led to the rapid development of effective vaccines. Within one year of the initial outbreak, multiple COVID-19 vaccines were authorized and deployed worldwide [1–3]. SARS-CoV-2 vaccines can be broadly classified into four types based on their antigen delivery mechanisms: mRNA vaccines, adenovirus vector vaccines, inactivated virus vaccines, and recombinant protein vaccines (see reviews [1–3] and the World Health Organization overview [4].

Since the onset of the pandemic, numerous studies have characterized the clinical manifestations of COVID-19 [5,6]. Acute infections can present with a wide range of symptoms, including fever, cough, fatigue, shortness of breath, gastrointestinal and neurological symptoms, as well as chemosensory dysfunction. Asymptomatic infections have also been reported [7,8]. Recovery trajectories vary considerably between individuals [9–12], with symptoms persisting for three months or longer after infection being commonly referred to as post-COVID syndrome, post-acute sequelae of COVID-19, or Long COVID [13,14]. This later became a Medical Subject Headings (MeSH) term, “Post-acute COVID-19 syndrome” (PCS). Although prevalence estimates vary due to the heterogeneous and non-specific nature of symptoms, recent studies suggest that PCS may affect up to 45% of individuals following SARS-CoV-2 infection [13,14].

Chemosensory dysfunction, encompassing impaired or distorted smell, taste, or chemesthetic perception, is a well-established feature of both acute COVID-19 and PCS [15–20]. Although chemosensory dysfunctions were previously observed with other viral infections of the upper respiratory system, their occurrence was relatively rare compared

to COVID-19 [21], in which up to 77% of COVID-19 patients reported smell dysfunction and 44% reported taste dysfunction [15,20,22–24].

Soon after COVID-19 vaccines became widely available, changes in chemosensory perception following vaccination were reported, including both improvement and worsening of symptoms, primarily in case reports and cohort studies. For example, a large U.S.-based study using electronic medical records from more than 96 million individuals reported extremely low incidence rates of post-vaccination smell (0.003%) and/or taste (0.009%) disturbance [25]. Another UK-based cohort study of individuals with PCS reported reduced odds of loss of smell (-12.5%) and loss of taste (-9.2%) after receiving adenovirus vector or mRNA vaccines [26]. Temporary olfactory dysfunction following vaccination has also been reported in isolated cases [27–29]. Although vaccine types and brands differ in their side-effect profiles [30], the relationship between COVID-19 vaccination and changes in chemosensory perception has not been systematically examined across diverse populations.

To address this gap, we conducted a large global online survey to investigate the relationship between COVID-19 vaccination and post-vaccination changes in chemosensory perception among individuals with and without COVID-19 related chemosensory impairment. We examined vaccination patterns across countries, changes in the general ability to smell and taste, and qualitative chemosensory distortion, as well as their relationships with vaccine-related side effects.

MATERIALS AND METHODS

Survey design

The survey started with collecting the date and brand of each COVID-19 vaccine received, followed by information on post-vaccination side effects. Participants selected side effects from a predefined list (including fever, headache, chills, diarrhea, vomit, stomach ache, joint ache, cough, sore throat, shortness of breath, muscle soreness, lightheadedness, dizziness, nausea, fatigue, nasal congestion, burning nose, heart problems, sleep disturbances, blood clots, skin rash, menstrual changes, brain fog, and others) and reported the duration of the side effects.

Given the focus on chemosensory outcomes, the survey included detailed questions on changes in smell, taste, and chemesthesis. Participants reported whether each modality had been affected by COVID-19 before vaccination, whether chemosensory dysfunction improved, worsened, or remained unchanged after vaccination, as well as the time of onset, and the duration of the changes. Participants also reported experiencing parosmia, phantosmia, and distorted taste. All chemosensory questions were answered separately for each vaccine dose received.

The survey was deployed in English, Chinese (traditional and simplified), French, German, Italian, Japanese, Persian, Russian, and Spanish via the online platform Qualtrics hosted at Indiana University (see **Supplementary Materials** for the full survey in English). The study was approved by the Global Consortium for Chemosensory Research (GCCR) Study Selection Team (ID: NDS006), the Institute Review Board of Indiana University (Protocol #: 15050), the Human Research Ethics Committee of the University of Queensland (Project ID: 2022/HE000839), and the Bioethics Committee at the A.N. Severtsov Institute of Ecology & Evolution of Russian Academy of Sciences (Protocol #.2022-63). The study was pre-registered on the Open Science Framework (OSF) [31].

Data collection and preprocessing

The online crowdsourced survey was distributed via social media, personal communication, GCCR newsletters (over 700 subscribers), and emails sent to over 6000 participants of prior GCCR studies [15,16] who had consented to be recontacted. A total of 2,955 responses were received between May 2022 and August 2023.

Open-text responses from non-English surveys were translated into English and then merged for analysis. Data preprocessing was conducted in accordance with the pre-registered exclusion criteria. A total of 1,602 respondents were excluded because they did not review all questions before exiting the survey (n = 1,066), reported pre-existing health conditions (n = 228), did not receive a COVID-19 vaccine (n = 206), were pregnant after the outbreak of COVID (a known modulator of chemosensory ability [32,33], n = 69) or younger than 18 years old (n = 33) (**Supplementary Figure 1**). Participants with pre-existing health conditions were those who selected any of the following: "Neurological pathologies", "Psychiatric pathologies", "Head and neck trauma", "Nasal sinus surgery", "Head and neck radiation", and "Impaired smell and taste perception" to the question "*Do you have below pre-existing conditions before COVID and/or before vaccination?*" One additional respondent was excluded due to non-compliance with study instructions. The final sample of 1,352 participants was included in the analyses.

Participants were required to answer questions related to vaccination status, while other items were optional, resulting in varying sample sizes across analyses.

Data analysis

172 Sample characteristics were summarized by age, sex, country of origin, vaccination status
173 (number of vaccination doses and boosters), vaccine brand (counts and percentages), and
174 pre-vaccination chemosensory status, *i.e.*, whether chemosensory perception was affected
175 by COVID-19 before vaccination. Post-vaccination chemosensory outcomes
176 (improvement, worsening, or no change) were reported for the full sample and stratified
177 by the presence or absence of COVID-19-related chemosensory impairment prior to
178 vaccination. Pre-existing chemosensory dysfunction was defined as unresolved COVID-
179 19-related smell or taste loss, or the presence of parosmia, phantosmia, or distorted taste
180 before vaccination.
181
182 Proportions of post-vaccination chemosensory changes were compared across vaccine
183 brands. Given country-level differences in vaccine availability, country- and region-
184 specific summaries (global regions and European regions) were also provided. Differences
185 in chemosensory outcomes across vaccine brands were assessed using Fisher's test of
186 homogeneity. Binomial tests were used to compare the proportion of participants reporting
187 improvement to the proportion reporting worsening for each vaccine brand. To evaluate
188 potential recall bias, follow-up durations (time between the vaccination date and survey
189 completion) were compared across outcome groups using one-way analysis of variance
190 (ANOVA).
191
192 For vaccine side effects, the frequency of each symptom was first summarized by vaccine
193 dose. Vaccine brands were grouped into four types: mRNA vaccines, adenovirus vector
194 vaccines, inactivated virus vaccines, and recombinant protein vaccines (see
195 **Supplementary Note**). Incidence rates of side effects were calculated across the first three
196 doses of vaccines within each type. Within each vaccine type, differences in side-effect

incidence across doses were evaluated using means of the k-proportions test with the Marascuilo Procedure. Lastly, the total number of reported side effects was compared across groups defined by post-vaccination changes in smell and taste using one-way ANOVA and pairwise t-tests.

All other analyses were performed in R (version 4.3.0) and RStudio (version 2023.03.0 Build 386), except for the k-proportions tests, which were performed using XLSTAT (version 2021.1.1).

RESULTS

Sample characteristics

The final analytic sample comprised 1,352 participants from 52 countries (**Supplementary Table 1)**. Most participants were aged between 25 and 64 years (71.6%), and 46.99% identified as cis women (**Supplementary Figure 2**). Pre-vaccination chemosensory impairments due to COVID-19 were reported by 599 of 1220 participants with complete taste and smell data (49%). Of these, 416 reported impairments in both smell and taste, and most of the remainder reported smell impairment only (**Supplementary Figure 3**). Pre-vaccination parosmia, phantosmia, and distorted taste were reported by 424, 265, and 380 participants, respectively (**Supplementary Tables 2 & 3)**. Country-specific prevalence estimates are provided in **Supplementary Table 4**.

Approximately half of the participants received two vaccine doses plus one booster (46.1%), 28.2% received two doses plus two boosters, 20% received two doses only, and 5.8% received a single dose (see **Figure 1A** for the country-specific vaccination status). Among the 1,200 participants who received at least two doses, two doses of Pfizer-

222 BioNTech was the most common combination (44.2%, n = 531), except in Russia,
223 Kazakhstan, Iran, the UK, and Switzerland, where Sputnik V, Sinopharm, Astra-Zeneca,
224 or Moderna predominated (**Figure 1B**). Among the 824 participants who received at least
225 two doses and one booster, Pfizer-BioNTech double doses were most often combined with
226 a booster from the same brand (n = 276, 33.5%) or with a booster from Moderna (n = 109,
227 13.2%). The third most common combination was two doses of Sputnik V plus a booster
228 of Sputnik Light (n = 59, 7.2%, **Supplementary Table 5**). Overall, Pfizer-BioNTech
229 accounted for 46.2% of all 3634 vaccine doses administered, followed by Sputnik V
230 (16.3%), Moderna (15.4%), AstraZeneca (8.9%), and Sinopharm (7.4%).
231
232 *Changes in chemosensory perception*
233 Among all participants, 94% or more reported no change in their general ability to smell
234 or taste perception after the first vaccine dose. When stratified by pre-existing COVID-19-
235 related chemosensory impairment, 90% participants with impairment and 97% without
236 impairment reported no changes (**Supplementary Figure 4**; **Supplementary Table 6**).
237 Among participants with pre-existing impairments, 3-8% reported improvement and 2-7%
238 reported worsening in smell or taste, depending on dose number (**Figure 2**).
239
240 For qualitative chemosensory symptoms, 66% or more of participants did not report
241 parosmia, phantosmia, or distorted taste before or after vaccination, and 2% or fewer
242 reported new onset following vaccination (**Supplementary Tables 2 & 3**). Among
243 participants with pre-existing qualitative impairments, improvement was reported by 11-
244 18% for parosmia, 20-29% for phantosmia, and 12-21% for distorted taste, depending on
245 dose, while worsening was reported by 3% or fewer (**Figure 3**).
246

Among the 75 participants who reported the timing and duration of post-vaccination chemosensory changes, approximately two-thirds indicated that the onset occurred on the day following vaccination, and most reported symptom duration longer than one month (**Supplementary Tables 2 and 3**). The time elapsed between the first vaccine dose and survey completion did not differ across participants reporting improvement, worsening, or no change (~20 months, $p > 0.05$; **Supplementary Table 7**).

Changes in chemosensory perception by vaccine brands

Among all participants, post-vaccination improvement in general smell after the first dose was most frequently reported following Moderna (9.6%, 95% CI [4.4, 14.8]) and least frequently following Sputnik V (0.8%, 95% CI [-0.3, 1.9]). Worsening was most frequent following Sputnik V (4.5%, 95% CI [1.9, 7.1]) and least frequent following Pfizer-BioNTech (1.3%, 95% CI [0.4, 2.3]) (**Supplementary Table 8**). Among participants with pre-existing smell dysfunctions (n = 432), improvement remained most frequent following Moderna (8 of 67, 11.9 %, 95% CI [4.2, 19.7]), while worsening was most frequent following Sputnik V (3 of 52, 5.8%, 95% CI [0.0, 12.1]). Similar patterns were observed after two doses of the same vaccines. Country- and region-specific summaries are provided in **Supplementary Table 9**. Post-vaccination changes in taste followed similar patterns (**Supplementary Tables 10 & 11**).

Although overall improvement rates differed across vaccine brands ($p < 0.05$), there was no evidence of systematic differences between improvement and worsening rates within individual brands. Given the small and unequal sizes of vaccine groups, these results should be interpreted with caution.

272 Among individuals with pre-existing parosmia, improvement after the first dose was most
273 frequent following Moderna (24.5%, 95% CI [12.9, 36.1]) and least frequent following
274 Astra-Zeneca (6.7%, 95% CI [-0.6, 14.0]) (**Table 1**). For phantosmia, improvement was
275 the highest following Moderna (34.4%, 95% CI [17.9, 50.8]) and lowest following Pfizer-
276 BioNTech (17.1%, 95% CI [11.1, 23.1]) (**Table 2**). For distorted taste, Sputnik showed
277 the highest proportions of both improvements (20.0%, 95% CI [6.7, 33.3]) and worsening
278 (8.6%, 95% CI [-0.7, 17.8]) (**Table 3**). Overall, improvement was more frequent than
279 worsening across qualitative chemosensory outcomes ($p < 0.001$), with no significant
280 differences across brands, except for parosmia after the first dose. Country- and region-
281 specific results are summarized in **Supplementary Tables 12-14**.
282
283 *Side effects of vaccination*
284 Across over 7,000 self-reported instances of post-vaccination side effects, the six most
285 reported symptoms were fatigue (34.6% after first dose), headache (32.6%), fever (32.0%),
286 muscle pain (29.0%), chills (25.2%), and joint pain (22.1%). Other reported symptoms
287 included menstrual changes (10% among cis women after the first dose), brain fog (6%),
288 and sleep disturbance (5%) (**Supplementary Figure 5**; **Supplementary Table 15**).
289
290 Side-effect incidence generally decreased with successive doses, with patterns varying by
291 vaccine types. Among participants receiving the same vaccine type across the first three
292 doses (*i.e.*, two doses and one booster), incidence rates for common side effects did not
293 differ across doses in the mRNA vaccine group ($n = 320$; $p > 0.05$). In contrast, significant
294 reductions were observed for fever and chills in the adenovirus vector vaccine group ($n =$
295 80) and headache in the inactivated virus vaccine group ($n = 51$) ($p < 0.05$)
296 (**Supplementary Figure 6; Supplementary Tables 16 and 17**).

297

298 Finally, the total number of reported side effects differed by chemosensory outcome.
299 Participants reporting worsening of smell or taste experienced a significantly higher
300 number of side effects compared with those reporting improvement and no change, for
301 both olfactory and gustatory modalities (**Supplementary Figure 7**; **Supplementary**
302 **Table 18**).

303

304 DISCUSSION

305 In this global retrospective survey study, we examined post-vaccination changes in
306 chemosensory perception among individuals with and without COVID-19-related
307 chemosensory impairment. More than 90% of participants with pre-existing COVID-19-
308 related smell or taste impairment reported no changes in their general chemosensory
309 function (*i.e.*, the ability to smell and taste) following vaccination. Among participants
310 with qualitative chemosensory distortions, a minority reported improvement, with over
311 20% reporting improvement in phantosmia, 11–18% in parosmia, and 12-21% in distorted
312 taste, depending on vaccine dose. Worsening of chemosensory symptoms was uncommon
313 across all modalities. Overall, these findings suggest that COVID-19 vaccination is
314 unlikely to adversely affect chemosensory function for most individuals and are consistent
315 with prior reports describing low-frequency post-vaccination chemosensory changes [27–
316 29,26].

317

318 These results help reconcile differences across the existing literature on post-vaccination
319 chemosensory outcomes. Large electronic medical record-based analyses have reported
320 very low incidence rates of post-vaccination smell or taste disturbance [25], likely
321 reflecting limited capture of chemosensory symptoms, particularly qualitative distortions,

322 in routine clinical coding. In contrast, cohort studies focused on individuals with PCS have
323 described modest changes in chemosensory symptoms following vaccination, including
324 both improvement and worsening [26–29]. By incorporating detailed self-reported
325 phenotyping of multiple chemosensory modalities, including parosmia and phantosmia,
326 our study provides greater sensitivity to qualitative symptom changes that are often
327 underrepresented in electronic health records. Differences in study design and outcome
328 ascertainment, therefore, likely account for variability across reports, supporting the view
329 that these findings are complementary rather than conflicting.
330
331 To further contextualize these chemosensory findings, we examined post-vaccination side
332 effects across vaccine types and assessed whether overall side-effect burden differed by
333 chemosensory outcome. The frequencies of reported side effects generally decreased with
334 the vaccine doses for most vaccine types, whereas side effects following mRNA vaccines
335 were most pronounced after the second dose. In addition to commonly reported symptoms,
336 menstrual cycle changes were reported by more than 8% of female participants after each
337 of the first three vaccine doses. Although prior work has suggested that menstrual cycle
338 changes may be related to the timing of vaccination [34], our findings are observational
339 and should be interpreted with caution. Brain fog, a symptom commonly reported in PCS,
340 was consistently reported by 4-6% of participants across vaccine doses. While previous
341 population-level studies suggest that vaccination may reduce the odds of brain fog as a
342 PCS symptom [35], further longitudinal and mechanistic investigation is needed to clarify
343 whether and how vaccination relates to cognitive symptoms [36].
344
345 From a public health perspective, these findings may help contextualize concerns about
346 potential chemosensory side effects of COVID-19 vaccination, particularly among

individuals with persistent post-COVID symptoms. The observation that chemosensory function remains unchanged for most individuals, with improvement occurring in a subset of those with qualitative chemosensory distortions, highlights the heterogeneity of post-COVID sensory trajectories. Although the pathophysiological mechanisms underlying vaccine-associated changes in chemosensory perception remain unclear [37], clear communication of these patterns may support informed decision-making and help address vaccine hesitancy in populations affected by post-COVID chemosensory dysfunction, without implying vaccination as a therapeutic intervention.

Several limitations should be considered when interpreting these findings. Recruitment through social media and recontacting participants from prior chemosensory studies may have introduced selection bias, potentially overrepresenting individuals with more persistent symptoms or greater motivation to report outcomes. Self-selection bias is also possible, which may limit the generalizability to the broader vaccinated population. All outcomes were self-reported, raising the possibility of recall bias and misclassification. Although self-report methods have been widely used to capture chemosensory outcomes in COVID-19 research [15–17], they lack the precision of standardized psychophysical assessments [24]. Additionally, COVID-19-related chemosensory dysfunction often improves gradually over time, making it difficult to distinguish vaccine-related changes from natural recovery. While we observed no association between time since vaccination and reported chemosensory changes, the absence of longitudinal tracking and objective baseline measures limits causal inference. The survey period spanned multiple SARS-CoV-2 variants and infection waves, which may differ in their chemosensory sequelae. Finally, cross-country differences in healthcare access, vaccine availability, and cultural norms may have influenced both exposure and symptom reporting. Collectively, these

limitations indicate that the findings are exploratory and should be interpreted with caution.

CONCLUSIONS

This global survey provides evidence that COVID-19 vaccination is associated with low-frequency changes in chemosensory perception among individuals with prior COVID-19-related chemosensory dysfunction, particularly for qualitative symptoms such as parosmia, phantosmia, and distorted taste. Most participants reported no change in their general sense of smell or taste following vaccination, and worsening of chemosensory symptoms was uncommon. Although the observational design precludes causal inference, these findings suggest that vaccination is unlikely to be associated with adverse chemosensory outcomes for most individuals and may coincide with improvement in a subset experiencing qualitative distortions. Further longitudinal studies with objective assessments (e.g., Sniffn' Sticks [38] or taste strips [39]) are needed to confirm these observations and to better inform public health communication around vaccination and post-COVID sensory symptoms.

ACKNOWLEDGEMENTS

LDH is supported by an Australian Research Council Early Discovery Researcher Award (DE240100014). We would like to thank Lisa Arvieu for assisting in translating the data collected from the French survey into English and Alyssa Bakke for emailing the survey to participants of previous GCCR studies.

AUTHORSHIP CONTRIBUTION

SK1, CMC, SK2, EC, MDG, JC, VP, VVV and LDH conceived the study. SK1, CMC,

SK2, EC, MDG, JC, VP, KO, VVV and LDH designed the original survey. SK1, CMC, SK2, EC, SP, MDG, VH, SC, VP, JC, GC, KO, VVV and LDH translated and implemented the survey. SK1 and LDH set up the online survey. SK1, CMC, MAK, TKL, SK2, IGK, JY, MDG, VVV and LDH analyzed data. SK1, CMC, MAK, TKL, SK2, IGK, JY, MDG, VP, VVV and LDH interpreted data. SK1, CMC, SK2, EC, MDG, VP, JC, VVV and LDH administrated project. SK1, CMC, MAK, TKL, SK2, IGK, EC, MDG, VVV and LDH wrote the original manuscript. All authors reviewed and approved the final version of the manuscript. SK1, Sachiko Koyama; SK2, Svetlana Kopishinskaia.

CONFLICT OF INTEREST

KO works at dsm-firmenich. The company had no influence on the study design or interpretation of results. All other authors had no conflict of interest.

FUNDING

LDH is supported by an Australian Research Council Early Discovery Researcher Award (DE240100014).

DATA AVAILABILITY

The data underlying this article will be shared on reasonable request to the corresponding author.

REFERENCES

1 Chen W-H, Strych U, Hotez PJ, *et al.* The SARS-CoV-2 Vaccine Pipeline: an Overview. *Curr Trop Med Rep*. 2020;7:61–4. doi: 10.1007/s40475-020-00201-6

2 Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. *Virus Res*. 2020;288:198114. doi: 10.1016/j.virusres.2020.198114

3 Russell RL, Pelka P, Mark BL. Frontrunners in the race to develop a SARS-CoV-2 vaccine. *Can J Microbiol*. 2021;67:189–212. doi: 10.1139/cjm-2020-0465

4 World Health Organization. 2025. COVID-19 vaccine tracker and landscape. World Health Organization. Available from: https://www.who.int/teams/blueprint/covid-19/covid-19-vaccine-tracker-and-landscape [accessed 11 September 2025]

5 Li L-Q, Huang T, Wang Y-Q, *et al.* COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol*. 2020;92:577–83. doi: 10.1002/jmv.25757

6 Sun P, Qie S, Liu Z, *et al.* Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. *J Med Virol*. 2020;92:612–7. doi: 10.1002/jmv.25735

7 Lai C-C, Liu YH, Wang C-Y, *et al.* Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. *J Microbiol Immunol Infect*. 2020;53:404–12. doi: 10.1016/j.jmii.2020.02.012

8 Zhao D, Wang M, Wang M, *et al.* Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China. *Int J Infect Dis*. 2020;99:219–25. doi: 10.1016/j.ijid.2020.07.082

9 Castanares-Zapatero D, Chalon P, Kohn L, *et al.* Pathophysiology and mechanism of long COVID: a comprehensive review. *Ann Med*. 2022;54:1473–87. doi: 10.1080/07853890.2022.2076901

10 Cogliandro V, Bonfanti P. Long COVID: lights and shadows on the clinical characterization of this emerging pathology. *New Microbiol*. 2024;47:15–27.

11 Golzardi M, Hromić-Jahjefendić A, Šutković J, *et al.* The Aftermath of COVID-19: Exploring the Long-Term Effects on Organ Systems. *Biomedicines*. 2024;12:913. doi: 10.3390/biomedicines12040913

12 Makhluf H, Madany H, Kim K. Long COVID: Long-Term Impact of SARS-CoV2. *Diagnostics (Basel)*. 2024;14:711. doi: 10.3390/diagnostics14070711

13 Hastie CE, Lowe DJ, McAuley A, *et al.* True prevalence of long-COVID in a nationwide, population cohort study. *Nat Commun*. 2023;14:7892. doi: 10.1038/s41467-023-43661-w

14 Sk Abd Razak R, Ismail A, Abdul Aziz AF, *et al.* Post-COVID syndrome prevalence: a systematic review and meta-analysis. *BMC Public Health*. 2024;24:1785. doi: 10.1186/s12889-024-19264-5

462 15 Parma V, Ohla K, Veldhuizen MG, *et al.* More Than Smell-COVID-19 Is Associated With
463 Severe Impairment of Smell, Taste, and Chemesthesis. *Chem Senses*. 2020;45:609–22. doi:
464 10.1093/chemse/bjaa041

465 16 Gerkin RC, Ohla K, Veldhuizen MG, *et al.* Recent Smell Loss Is the Best Predictor of
466 COVID-19 Among Individuals With Recent Respiratory Symptoms. *Chem Senses*.
467 2021;46:bjaa081. doi: 10.1093/chemse/bjaa081

468 17 Ohla K, Veldhuizen MG, Green T, *et al.* A follow-up on quantitative and qualitative
469 olfactory dysfunction and other symptoms in patients recovering from COVID-19 smell
470 loss. *Rhinology*. 2022;60:207–17. doi: 10.4193/Rhin21.415

471 18 Cooper KW, Brann DH, Farruggia MC, *et al.* COVID-19 and the Chemical Senses:
472 Supporting Players Take Center Stage. *Neuron*. 2020;107:219–33. doi:
473 10.1016/j.neuron.2020.06.032

474 19 Rouadi PW, Idriss SA, Bousquet J. Olfactory and taste dysfunctions in COVID-19. *Curr*
475 *Opin Allergy Clin Immunol*. 2021;21:229–44. doi: 10.1097/ACI.0000000000000735

476 20 Nguyen H, Albayay J, Höchenberger R, *et al.* Covid-19 affects taste independent of taste–
477 smell confusions: results from a combined chemosensory home test and online survey from
478 a large global cohort. *Chemical Senses*. 2023;48:bjad020. doi: 10.1093/chemse/bjad020

479 21 Koyama S, Kondo K, Ueha R, *et al.* Possible Use of Phytochemicals for Recovery from
480 COVID-19-Induced Anosmia and Ageusia. *IJMS*. 2021;22:8912. doi:
481 10.3390/ijms22168912

482 22 Moein ST, Hashemian SM, Mansourafshar B, *et al.* Smell dysfunction: a biomarker for
483 COVID-19. *Int Forum Allergy Rhinol*. 2020;10:944–50. doi: 10.1002/alr.22587

484 23 Butterworth J. Intracellular and extracellular alpha-D-mannosidase activity of cultured skin
485 fibroblasts: relationship to cystic fibrosis. *Clin Chim Acta*. 1980;108:347–53. doi:
486 10.1016/0009-8981(80)90340-x

487 24 Hannum ME, Ramirez VA, Lipson SJ, *et al.* Objective sensory testing methods reveal a
488 higher prevalence of olfactory loss in COVID-19–positive patients compared to subjective
489 methods: A systematic review and meta-analysis. *Chemical Senses*. 2020;bjaa064. doi:
490 10.1093/chemse/bjaa064

491 25 Gallagher TJ, Parikh M, Herrera K, *et al.* Association of COVID-19 Vaccination With
492 Changes in Smell and Taste. *Otolaryngol Head Neck Surg*. 2024;171:1240–4. doi:
493 10.1002/ohn.833

494 26 Ayoubkhani D, Bermingham C, Pouwels KB, *et al.* Trajectory of long covid symptoms after
495 covid-19 vaccination: community based cohort study. *BMJ*. 2022;e069676. doi:
496 10.1136/bmj-2021-069676

497 27 Konstantinidis I, Delides A, Tsakiropoulou E, *et al.* Short-Term Follow-Up of Self-Isolated
498 COVID-19 Patients with Smell and Taste Dysfunction in Greece: Two Phenotypes of
499 Recovery. *ORL J Otorhinolaryngol Relat Spec*. 2020;1–9. doi: 10.1159/000511436

500 28 Konstantinidis I, Tsakiropoulou E, Hähner A, *et al.* Olfactory dysfunction after coronavirus

501 disease 2019 (COVID-19) vaccination. *Int Forum Allergy Rhinol*. 2021;11:1399–401. doi:
502 10.1002/alr.22809

503 29 Keir G, Maria NI, Kirsch CFE. Unique Imaging Findings of Neurologic Phantosmia
504 Following Pfizer-BioNtech COVID-19 Vaccination: A Case Report. *Top Magn Reson*
505 *Imaging*. 2021;30:133–7. doi: 10.1097/RMR.0000000000000287

506 30 Munro APS, Janani L, Cornelius V, *et al.* Safety and immunogenicity of seven COVID-19
507 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2
508 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *The*
509 *Lancet*. 2021;398:2258–76. doi: 10.1016/S0140-6736(21)02717-3

510 31 Hwang L-D, Farruggia MC, Cantone E, *et al.* Influences of COVID-19 vaccination on post-
511 acute sequelae of COVID-19. Published Online First: 23 May 2022. doi:
512 10.17605/OSF.IO/5D9KN

513 32 Cameron EL. Pregnancy and olfaction: a review. *Front Psychol*. 2014;5:67. doi:
514 10.3389/fpsyg.2014.00067

515 33 Choo E, Dando R. The Impact of Pregnancy on Taste Function. *Chem Senses*. 2017;42:279–
516 86. doi: 10.1093/chemse/bjx005

517 34 Edelman A, Boniface ER, Male V, *et al.* Timing of Coronavirus Disease 2019 (COVID-19)
518 Vaccination and Effects on Menstrual Cycle Changes. *Obstet Gynecol*. 2024;143:585–94.
519 doi: 10.1097/AOG.0000000000005550

520 35 van der Feltz-Cornelis C, Turk F, Sweetman J, *et al.* Prevalence of mental health conditions
521 and brain fog in people with long COVID: A systematic review and meta-analysis. *Gen*
522 *Hosp Psychiatry*. 2024;88:10–22. doi: 10.1016/j.genhosppsych.2024.02.009

523 36 Shimohata T. Neuro-COVID-19. *Clin Exp Neuroimmunol*. 2022;13:17–23. doi:
524 10.1111/cen3.12676

525 37 Lechien JR, Diallo AO, Dachy B, *et al.* COVID-19: Post-vaccine Smell and Taste
526 Disorders: Report of 6 Cases. *Ear Nose Throat J*. 2024;103:NP104–7. doi:
527 10.1177/01455613211033125

528 38 Hummel T, Sekinger B, Wolf SR, *et al.* "Sniffin" sticks': olfactory performance assessed by
529 the combined testing of odor identification, odor discrimination and olfactory threshold.
530 *Chem Senses*. 1997;22:39–52. doi: 10.1093/chemse/22.1.39

531 39 Landis BN, Welge-Luessen A, Brämerson A, *et al.* "Taste Strips" - a rapid, lateralized,
532 gustatory bedside identification test based on impregnated filter papers. *J Neurol*.
533 2009;256:242–8. doi: 10.1007/s00415-009-0088-y

534

535

536

537

FIGURES



Figure 1. Distribution of vaccination status of participants (A) and combinations of the first two doses received (B) in different countries. Only countries with ≥10 respondents were included. The number in brackets represents the total number of vaccinated participants per country.



Figure 2. Changes in the senses of smell and taste after each dose of vaccine in participants with pre-existing chemosensory impairment due to COVID-19. The number of participants per condition for the first three doses is shown in parentheses.



Figure 3. Changes in parosmia/phantosmia/distorted taste after each dose of vaccine in participants with pre-existing sensory impairment due to COVID-19. The number of participants per condition for the first three doses is shown in parentheses.

558 TABLES
559
560 **Table 1. Post-vaccination changes in pre-existing parosmia by vaccine brands.**

After the first dose of vaccine						
Brands	**Vaccinated participants**	**Improved parosmia**		**Worsened parosmia**		**Improved vs worsened[d]**
	N	**N**	**Proportion**	**N**	**Proportion**	**P**
Pfizer-BioNTech[a]	224	20	8.9%	4	1.8%	0.002
Moderna[a]	53	13	24.5%	0	0%	<0.001
Sputnik V[b]	53	8	15.1%	4	7.5%	0.39
Astra-Zeneca[b]	45	3	6.7%	1	2.2%	0.63
Total	375	44	11.7%	9	2.4%	<0.001
Fisher's Exact test of homogeneity, p-value[c]		p = 0.01		p = 0.08		
After the second dose of vaccine						
Pfizer-BioNTech[a] × 2	176	24	13.6%	1	0.6%	<0.001
Moderna[a] × 2	35	5	14.3%	0	0%	0.06
Sputnik V[b] × 2	38	6	15.8%	3	7.9%	0.51
Astra-Zeneca[b] × 2	25	1	4.0%	1	4.0%	1
Total	274	36	13.1%	5	1.8%	<0.001
Fisher's Exact test of homogeneity, p-value[c]		p = 0.54		p = 0.02		

561 Note: The most common 4 brands were included. All participants who received the first two doses of the same
562 vaccine were included in the analysis of post-vaccination changes after the first dose of vaccine. [a]mRNA type
563 vaccines; [b]adenovirus vector vaccines. [c]Fisher's test of homogeneity was used to compare the proportions of
564 improvement or worsening between all groups. [d]Binomial tests comparing the % improvement and % worsening
565 with two-sided p-values reported.

566

567 **Table 2. Post-vaccination changes in pre-existing phantosmia by vaccine brands**

Brands	Vaccinated participants	Improved phantosmia		Worsened phantosmia		Improved vs worsened[d]
	N	N	Proportion	N	Proportion	P
After the first dose of vaccine						
Pfizer-BioNTech[a]	152	26	17.1%	4	2.6%	<0.001
Moderna[a]	32	11	34.4%	3	9.4%	0.06
Astra-Zeneca [b]	30	6	20.0%	0	0%	0.03
Sputnik V[b]	23	6	26.1%	2	8.7%	0.29
Total	237	49	20.7%	9	3.8%	<0.001
Fisher's Exact test of homogeneity, p-value[c]		p = 0.15		p = 0.09		
After the second dose of vaccine						
Pfizer-BioNTech[a] × 2	119	21	17.6%	6	5.0%	0.006
Moderna[a] × 2	22	7	31.8%	1	4.5%	0.07
Astra-Zeneca[b] × 2	18	1	5.6%	0	0%	1
Sputnik V[b] × 2	14	5	35.7%	0	0%	0.06
Total	173	34	19.7%	9	5.2%	<0.001
Fisher's exact test of homogeneity, p-value[c]		p = 0.07		p = 1		

568 Note: The most common 4 brands were included. All participants who received the first two doses of the same
569 vaccine were included in the analysis of post-vaccination changes after the first dose of vaccine. [a]mRNA type
570 vaccines; [b]adenovirus vector vaccines. [c]Fisher's test of homogeneity was used to compare the proportions of
571 improvement or worsening between all groups. [d]Binomial tests comparing the % improvement and % worsening
572 with two-sided p-values reported.

573

574

575

576

577

578

579

580

581

582

583

584

585 **Table 3. Post-vaccination changes in pre-existing distorted taste by vaccine brands**

After the first dose of vaccine						
Brands	**Vaccinated participants**	**Improved distorted taste**		**Worsened distorted taste**		**Improved vs worsened[d]**
	N	**N**	**Proportion**	**N**	**Proportion**	**P**
Pfizer-BioNTech[a]	213	24	11.3%	4	1.9%	<0.001
Moderna[a]	48	7	14.6%	2	4.2%	0.18
Astra-Zeneca[b]	43	5	11.6%	0	0%	0.06
Sputnik V[b]	35	7	20.0%	3	8.6%	0.34
Total	339	43	12.7%	9	2.7%	<0.001
Fisher's Exact test of homogeneity, p-value[c]		p = 0.47		p = 0.08		
After the second dose of vaccine						
Pfizer-BioNTech[a] × 2	168	20	*11.9%*	5	3.0%	0.004
Moderna[a] × 2	34	4	*11.8%*	1	2.9%	0.38
Astra-Zeneca[b] × 2	26	1	*3.8%*	0	0%	1.00
Sputnik V[b] × 2	23	4	*17.4%*	0	0%	0.13
Total	251	29	11.6%	9	3.6%	0.002
Fisher's Exact test, p-value[c]		p = 0.50		p = 1		

586 Note: The most common 4 brands were included. All participants who received the first two doses of the same
587 vaccine were included in the analysis of post-vaccination changes after the first dose of vaccine. [a]mRNA type
588 vaccines; [b]adenovirus vector vaccines. [c]Fisher's test of homogeneity was used to compare the proportions of
589 improvement or worsening between all groups. [d]Binomial tests comparing the % improvement and % worsening
590 with two-sided p-values reported.

591

592